Skip to main content
Premium Trial:

Request an Annual Quote

New Releases: Apr 13, 2011


Originally published April 11.

Precision Therapeutics has launched a new product line, called BioSpeciFx, with which it hopes to personalize cancer treatments.

According to the company, BioSpeciFx comprises sets of tests that gauge genomic and proteomic markers in patients' cells. Precision Therapeutics plans to use the information generated by BioSpciFx in combination with its ChemoFx test to learn more about patients' tumors and personalize their therapy. ChemoFx assesses "the functional characteristics" of a tumor, many of which aren't accounted for via biomarker testing, to provide information about whether a patient is sensitive or resistant to chemotherapy.

"When combined, both products offer a complementary sum of information which will enable physicians to look at both the relevant molecular targets as well as the synergistic activity of drug combinations on the entire cell," the company said in a statement.

"The Comprehensive Tumor Profile developed by Precision presents the most complete offering available to cancer patients today, because it integrates both genomic and proteomic information with the functional profiling of ChemoFx," Sean McDonald, CEO of Precision Therapeutics, said in a statement.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.